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The NADH:ubiquinone oxidoreductase or complex I of the mitochondrial respiratory chain is an intricate enzyme with a vital role in energy
metabolism. Mutations affecting complex I can affect at least three processes; they can impair the oxidation of NADH, reduce the enzyme's ability
to pump protons for the generation of a mitochondrial membrane potential and increase the production of damaging reactive oxygen species. We
have previously developed a nematode model of complex I-associated mitochondrial dysfunction that features hallmark characteristics of
mitochondrial disease, such as lactic acidosis and decreased respiration. We have expressed the Saccharomyces cerevisiae NDI1 gene, which
encodes a single subunit NADH dehydrogenase, in a strain of Caenorhabditis elegans with an impaired complex I. Expression of Ndi1p produces
marked improvements in animal fitness and reproduction, increases respiration rates and restores mitochondrial membrane potential to wild type
levels. Ndi1p functionally integrates into the nematode respiratory chain and mitigates the deleterious effects of a complex I deficit. However, we
have also shown that Ndi1p cannot substitute for the absence of complex I. Nevertheless, the yeast Ndi1p should be considered as a candidate for
gene therapy in human diseases involving complex I.
© 2007 Elsevier B.V. All rights reserved.Keywords: Mitochondria; Membrane potential; Nematode; NADH:ubiquinone oxidoreductase; DiS-C3(3)1. Introduction
Structural and functional deficiencies of the mammalian
NADH:ubiquinone oxidoreductase (Complex I) are causative of
a number of human mitochondrial diseases, including cardiomy-
opathies, encephalomyopathies and neurodegenerative disorders
[1–4]. Complex I, located in the inner mitochondrial membrane,
is composed of 45 subunits, one flavin mononucleotide (FMN)
cofactor and eight iron–sulfur clusters [5]. Defects in complex I
can impair the oxidation of NADH and proton pumping, leading
to metabolic imbalances and a reduced proton electrochemical
gradient across the inner membrane. In addition, complex I
defects are often associated with an elevated production of
reactive oxygen species (ROS) [6].⁎ Corresponding author. Tel.: +1 780 492 4853; fax: +1 780 492 0886.
E-mail address: bernard.lemire@ualberta.ca (B.D. Lemire).
0005-2728/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbabio.2007.07.003The free-living soil nematode Caenorhabditis elegans has the
advantages of a short life cycle, a simple anatomy and a mito-
chondrial respiratory chain (MRC) composed of subunits with
high sequence identities with their human homologs [7–10]. We
have developed a C. elegans model of complex I deficiency to
further understand the bioenergetic and biochemical conse-
quences of mitochondrial disease [11]. These mitochondrial
mutants contain missense mutations in the nuo-1 gene, the
nematode ortholog of the human NDUFV1 gene, which encodes
the 51-kDa FMN-containing, active site subunit of complex I [11].
In this study, we used nematode strains with A352V and A443F
amino acid substitutions in the NUO-1 protein to investigate the
utility of gene therapy in treating complex I dysfunction.
In contrast to mammals, the mitochondria of Saccharomyces
cerevisiae lack complex I and instead contain single subunit
rotenone-insensitive NADH:ubiquinone oxidoreductases that do
not translocate protons [12–14]. The S. cerevisiaeNdi1p, with its
Fig. 1. Brood size analysis of transgenic strains. Hermaphrodites were incubated
at 20 °C and the number of progeny produced was counted. Values are the
average of a minimum of 34 broods counted. ⁎⁎Pb0.01 when compared with
the LB54 control strain using a two-sample t-test.
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catalyzes the oxidation of NADH and the reduction of ubiquinone
[12]. It contains noncovalently bound flavin adenine dinucleotide
(FAD) and lacks iron sulfur clusters. Ndi1p is synthesized as a
513-amino acid precursor protein containing a 26-residue amino-
terminal signal sequence responsible for its import into mito-
chondria [15]. Ndi1p catalyzes a two-electron transfer reaction
that is believed to avoid the formation of an ubisemiquinone
intermediate and thus minimize electron leakage and the for-
mation of ROS [16]. Based on its catalytic mechanism and on its
simple structure, it has been suggested that Ndi1p may offer a
practical gene therapy approach for treating complex I deficiency.
Ndi1p expression should restore NADH oxidation without
stimulating ROS production [15]. Gene therapy with Ndi1p will
be applicable to deficiencies arising from mutations in either
nuclear or mitochondrial DNA encoded complex I subunits.
Heterologous expression of Ndi1p in bacteria, plants and fungi
does not affect the endogenous complex I [15].
In this study, we demonstrate that Ndi1p expression results in
significantly improved reproductive success, better survival under
conditions of oxidative stress, fewer signs of premature aging,
increased respiration rates and a complete restoration of the in vivo
mitochondrial membrane potential in C. elegans nuo-1 mutants.
However, Ndi1p is not able to fully replace complex I and cannot
support larval development when complex I is missing. We
suggest that gene therapy approaches involving Ndi1p may offer
substantial clinical benefits in cases of complex I deficiency.
2. Materials and methods
2.1. Worm strains and maintenance
C. elegans strains were cultured on Nematode Growth Medium supplemented
with 1 mg/ml G418 antibiotic to select for the retention of the extrachromosomal
arrays [8]. We used the following C. elegans strains: N2 (Bristol) wild type;
LB25 (also referred to as A352V), nuo-1(ua1) II, unc-119(ed3) III, uaEx25
[p016bA352V]; and LB27 (also referred to as A443F) nuo-1(ua1) II, unc-119(ed3)
III, uaEx27[p016bA443F]; LB52, nuo-1(ua-1) II, unc-119(ed3) III, uaEx25
[p016bA352V], uaEx30[Plet-858::NDI1, pDP#SU006, pTG96, pPD118.25NEO];
LB53, nuo-1(ua-1) II, unc-119(ed3) III, uaEx25[p016bA352V], uaEx31[Pnuo-1::
NDI1, pDP#SU006, pTG96, pPD118.25NEO]; LB54, nuo-1(ua-1) II, unc-119
(ed3) III, uaEx25[p016bA352V], uaEx32[pDP#SU006, pTG96, pPD118.25NEO].
uaEx25 and uaEx27 are extrachromosomal arrays carrying the nuo-1(A352V) and
the nuo-1(A443F) point mutations, respectively.
2.2. Plasmid constructs and the generation of transgenic lines
The Plet-858::NDI1 expression plasmid was constructed by inserting the
entire NDI1 gene downstream of a 3.5-kb fragment encoding the let-858
promoter using Gateway Cloning technology [17]. The Pnuo-1::NDI1
expression plasmid was constructed by inserting the NDI1 gene downstream
of a 0.6-kb fragment encoding the nuo-1 promoter region [17]. NDI1 expression
constructs were injected independently into the syncytial gonads of young adult
LB25 hermaphrodites alongwith the reporter plasmids, pDP#SU006, pTG96 and
pPD118.25NEO. pDP#SU006 expresses GFP under the control of the F25B3.3
promoter, which is active in the nervous system [17,18]. pTG96 expresses a sur-
5::GFP fusion that localizes to nuclei [19]. pPD118.25NEO contains the
neomycin resistance gene under control of the ubiquitous let-858 promoter. Six
independent transgenic lines were isolated for eachNDI1 construct and two were
chosen for further study. A control line, LB54, contains the reporter plasmids but
does not contain either of the NDI1 expression plasmids. In all cases except in
Fig. 3, data from independent lines were combined.2.3. Phenotypic analyses
Brood size measurements were conducted as described [11]. Morphological
analysis was performed by mounting worms onto 2% agarose pads for
observation using a Zeiss Axioskop-2 research microscope equipped with
fluorescence optics, Nomarski imaging and a SPOT-2 digital camera (Carl Zeiss
Canada Ltd., Calgary, Canada).
2.4. Western blot analyses
Mitochondria isolated from synchronized L4 larvae were isolated and used
for Western blot analysis (100 μg protein per lane) as previously described [11].
The yeast strain, YNN214 was used as a positive control for the presence of
Ndi1p, while a knockout strain, NDI1Δ was used as a negative control.
2.5. Polarographic analyses
Oxygen consumption rates were measured using a Strathkelvin 1302 oxygen
electrode with a MT200 Mitocell respiration chamber (Strathkelvin Instruments,
Glasgow, UK). Whole-animal respiration rates were obtained using extensively-
washed, bacteria-free synchronized L4 larvae [17]. A minimum of ten replicates
per strain was performed. Whole mitochondria for respiration analyses were
isolated frombacteria-freeworms grown in liquid culture.Mitochondriawere lysed
by hypotonic shock and ultrasonication to allow access of NADH to the matrix-
facing active site of complex I and respiration rates were measured as described
[11]. Complex I-specific respiration was measured as the NADH-dependent,
rotenone-sensitive rate of oxygen consumption.
2.6. Oxidative stress assays
The survival of transgenic strainswasmeasured at room temperature by placing
L1 larvae on seeded NGM plates in a chamber continuously flushed with 100%
oxygen [17]. Survival was measured after 5 days as the fraction of L1 larvae that
developed into adults. A minimum of ten trials were performed per strain.
2.7. Membrane potential determination
Mitochondrial membrane potential was determined using the cationic
fluorescent probe, diS-C3(3) (3,3′-dipropylthiocarbocyanine iodide; Sigma-
Aldrich Chemie GmbH (Buchs, Switzerland)). Healthy, well-fed, mixed staged
worms were harvested from plates by washing with M9 [20] and centrifuging at
275×g. Worms were incubated in M9 for 30 min with gentle shaking to allow
digestion of bacteria, washed and stained for 1 h in 4×10−6 M diS-C3(3). The
worms were washed four times in M9 and fluorescence measurements were
Table 1
Ndi1p expression increases respiration rates in living animals
Strain Respiration rate a
LB52 6.4±2.1 ⁎⁎
LB53 5.6±0.7 ⁎⁎
LB54 3.3±1.4
a Values are expressed as nmol O2 consumed min
−1 mg protein−1 and are the
means±SD of a minimum of ten trials.
⁎⁎ Pb0.01 when compared to the control line LB54 using a two-sample t-test.
Fig. 2. Survival of transgenic strains under hyperoxia. L1 larvae were incubated
at room temperature in a tank continuously flushed with 100% oxygen for
5 days. Animals not responding to touch were scored as dead. Values are the
means of a minimum of ten trials with at least 75 animals per trial. ⁎⁎Pb0.01
when compared with the LB54 control strain using a two-sample t-test.
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3. Results
We expressed the NDI1 gene, which encodes the single
subunit S. cerevisiae NADH dehydrogenase, under the control
of the let-858 and nuo-1 promoters. Both promoters will drive
constitutive expression [17,22]. LB25, also referred to as
A352V, is the parent strain for our studies; it is homozygous for
the lethal nuo-1(ua1) allele and carries an extrachromosomal
array with a Ala352Val substituted nuo-1 gene [17]. LB52 is
derived from LB25 by transformation with the Plet858::NDI1
construct; LB53 is derived from LB25 by transformation with
Pnuo-1::NDI1. LB54, the control strain, was transformed
with the reporter plasmids only.
NDI1 expression improves the overall health and fertility of
the A352V mitochondrial mutants [17]. Significant increases of
47% and 36% in the average brood sizes of LB52 and LB53,
respectively were observed in comparison with LB54 (Fig. 1).
We have previously shown that the A352V mutant consumes
oxygen at approximately half the wild-type rate [11]. We
measured the oxygen consumption rates of the NDI1 expressing
strains. LB52 and LB53 showed 94% and 70% higher
respiration rates than LB54, respectively (Table 1).
Unlike complex I, Ndi1p catalyzes the oxidation of NADH
in a rotenone-insensitive reaction. We predicted that the
rotenone-insensitive NADH oxidase activity should increase
in NDI1 expressing strains. Isolated mitochondria of LB52 and
LB53 show an increase in the total NADH-dependent rates of
oxygen consumption (Table 2), consistent with the increased
respiration rates seen in live animals (Table 1). The rotenone-
insensitive respiration rates, which have increased 2–3 fold inTable 2
Ndi1p expression increases rotenone-insensitive respiration rates in isolated
mitochondria
Strain a Total respiration b Rotenone-insensitive b Rotenone-sensitive b, c
LB52 48±24 (100%) 40±16 (83%) ⁎⁎ 8±23 (17%)
LB53 29±10 (100%) 22±4 (76%) ⁎⁎ 7±9 (24%)
LB54 23±12 (100%) 12±8 (52%) 11±18 (48%)
a The number of replicates performed are 10, 16 and 14 for LB52, LB53 and
LB54, respectively.
b Values are expressed as nmol O2 min
−1 mg protein−1 and are the means±SD.
c Rotenone-sensitive rates are calculated as the differences between the total
and the rotenone-insensitive rates.
⁎⁎ Pb0.01 when compared with the LB54 control strain using a two-sample
t-test.the Ndi1p expressing strains, account for the entire increases.
The rotenone-sensitive rates, attributable to complex I are un-
changed in LB52 and LB53 compared to LB54 (Table 2).
Mitochondria generate ROS as a normal but toxic by-product
of respiration [23]. Mitochondrial dysfunction can result in the
elevated production of ROS, leading to increased damage of
cellular proteins, lipids andDNA [24].We showed previously that
the imposition of an exogenous oxidative stress, such as a 100%
oxygen atmosphere, on the nuo-1(A352V)mutant overwhelms its
already challenged defense mechanisms and results in decreased
survival [25]. Ndi1p is believed to catalyze ubiquinone reduction
using a two-electron transfer mechanism, thus eliminating the
formation of an ubisemiquinone intermediate that might con-
tribute to reactive oxygen species formation. We measured the
survival of the Ndi1p expressing strains under hyperoxia; 62% of
LB52 and 70% of LB53 animals survived after 5 days in 100%
oxygen, while only 39%ofLB54 animals survived (Fig. 2). These
results indicate that Ndi1p expression renders LB52 and LB53
more resistant to oxidative stress, suggesting that Ndi1p dimin-
ishes ROS generation under hyperoxic conditions and probably
also under normoxic conditions.
Expression of Ndi1p has marked effects onC. elegans fertility
and resistance to oxidative stress. It stimulates respiration in live
animals and in isolated mitochondria. With an antibody directed
against Ndi1p, we used Western blot analysis to investigate
whether Ndi1p could be detected inworms (Fig. 3).We detected a
strong band migrating at∼53 kDa in mitochondria from the wild
type yeast strain YNN214 that was absent in the ΔNDI1 mito-
chondria. We detected markedly variable amounts of a 53-kDa
band in the LB52 and LB53 mitochondria isolated fromFig. 3. Ndi1p is expressed in transgenic C. elegans strains. Mitochondrial
protein from two independent lines of LB52 (lanes 1, 2), LB53 (lanes 3, 4) and
LB54 (lanes 5, 6) was loaded (100 μg per lane). Yeast mitochondrial protein
from the wild type strain, YNN214 (lane 7) and from the NDI1 deletion strain
(ΔNDI1, lane 8) was also loaded as controls.
Fig. 4. Vacuole formation is delayed by Ndi1p expression. A classification system was developed to assess the severity of vacuolar structure formation. Representative
examples are shown in A–C. (A) No vacuoles; (B) Moderate phenotype (1–3 vacuoles); (C) Severe phenotype (4 or more vacuoles). Representative Nomarski
photographs of the head regions of 1-day-old hermaphrodites are shown in D–F. (D) LB52, (E) LB53, (F) LB54. Representative Nomarski photographs of the head
regions of 2-day-old hermaphrodites are shown in G-I. (G) LB52, (H) LB53, (I) LB54. Bars=15 μm. The metacarpus of the pharynx is indicated with a black arrow
and examples of vacuolar structures are indicated with white arrows.
Table 3
Ndi1p expression reduces the formation of vacuolar structures
Strain % None % Moderate a % Severe a
1 day b 2 days c 1 day b 2 days c 1 day b 2 days c
LB52 79.2 59.2 12.3 31.6 8.5 9.2
LB53 55.4 66.5 30.5 27.3 14.1 6.2
LB54 40.6 28.2 39.3 38.5 20.1 33.3
a One- and 2-day-old adults were examined and classified as moderate when
they contained 1–3 vacuolar structures and as severe when they contained 4 or
more structures.
b The numbers of LB52, LB53 and LB54 animals scored was 221, 208 and
252, respectively.
c The numbers of LB52, LB53 and LB54 animals scored was 219, 253 and
297, respectively.
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expression levels of Ndi1p, the efficiency of Ndi1p targeting to
mitochondria or Ndi1p assembly with its flavin cofactor into the
C. elegans mitochondrial membrane differ between transgenic
lines. Alternatively, Ndi1p may be susceptible to degradation in a
non-native membrane. The amount of immunologically-detect-
able Ndi1p does not accurately reflect the amount of functional
Ndi1p present. We did not detect any significant amount of
staining at 53 kDa in any of our LB54 control lines.
MRC function is closely related to aging and lifespan
determination [9]. The A352V mutant shows signs of premature
aging as a young adult [11]. The body wall muscle appears to
degenerate and large vacuolar structures form beneath the cuticle
(Fig. 4). We counted the number of vacuolar structures seen in 1-
day- and 2-day-old control or Ndi1p-expressing adults. Worms
were classified by the number of vacuolar structures present in the
vicinity of the pharynx.Wormswith 1–3 vacuolar structures were
scored as moderate (Fig. 4B) while worms with 4 or morewere scored as severe (Fig. 4C). One day into adulthood, we
measured a decrease in the number of LB52 (9%) and LB53
(14%) worms scored as severe compared to LB54 (20%) animals
(Fig. 4D–F; Table 3). The number of vacuolar structures
Fig. 5. Worms expressing Ndi1p have an increased membrane potential. The
λmax values of worms stained with diS-C3(3) were determined; the λmax values
are proportional to the mitochondrial membrane potential. LB25 is the parent
strain for LB52–LB54. LB27 is another nuo-1 mutant carrying an A443F
mutation. Values are means of 13, 18, 10, 9, 6 and 14 replicates for N2, LB52,
LB53, LB25, LB27 and LB54, respectively. ⁎⁎Pb0.01 when compared with the
LB54 control strain using a two-sample t-test.
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old LB52 or LB53 adults (Fig. 4G–I; Table 3). The percentage of
2-day-old LB54 animals that remain vacuole free is only 28%,
while 59% and 67% of LB52 and LB53 animals remain vacuole-
free, respectively.
In previouswork, we demonstrated that the A352Vmutant has
a lower level of ATP [17] and more recently, that it has a lower
mitochondrial membrane potential in vivo [21]. We expected that
Ndi1p expression would at least partially restore the mitochon-
drial membrane potential as NADH oxidation would be coupled
to proton translocation, not through Ndi1p itself, but through
complexes III and IV. We used a fluorescence based assay to
measure the mitochondrial membrane potential-dependent accu-
mulation of diS-C3(3) in living animals. This assay exploits the
spectral properties of diS-C3(3); its fluorescence emission
maximum (λmax) and its fluorescence intensity at the maximum
(Imax) respond to changes in membrane potential. The control
strain, LB54 as well as the two original nuo-1 mutants LB25
(A352V) and LB27 (A443F) have λmax values of approximately
575 nm (Fig. 5). The λmax values for LB52 and LB53 are 2 nm
higher than that of LB54 (Fig. 5). Thewild type strain, N2 also has
a λmax of 577 nm. These results indicate that Ndi1p functionally
interacts with the nematode respiratory chain and contributes to
the formation of the mitochondrial membrane potential in vivo.
4. Discussion
MRCbiogenesis is a complex process involving over 70 genes
encoded in 2 genomes. Mutations affecting MRC function
produce a wide range of disorders, making the treatment of
mitochondrial disease a challenge. Gene replacement therapy has
been advocated as a strategy for treating mitochondrial disease
[26–31]. One form of gene therapy is to express and deliver a
protein to the damaged mitochondria that will functionally
substitute for the affected MRC complex. In this work, we have
utilized this strategy to deliver the S. cerevisiae Ndi1p to the
mitochondria of complex I-deficient C. elegans.Gene therapy experiments with the yeast Ndi1p have revealed
its remarkable versatility. It can act as a functional member of the
Escherichia coli respiratory chain [6]. It can restore NADH
oxidase activity in complex-I deficient Chinese hamster cells [32]
or in human C4T cells, which contain a homoplasmic frameshift
mutation in the mitochondrial ND4 gene [26,33]. Ndi1p
expression in human embryonic kidney cells does not interfere
with the levels of endogenous complex-I [34]. An adeno-
associated virus vector system has been used to successfully
deliver and express the NDI1 gene in non-proliferating human
cells [35]. More recently, NDI1 gene expression was shown to be
beneficial in a murine model of chemically-induced complex I
deficiency that mimics Parkinson disease [36]. Finally, complex I
dysfunction or inhibition can lead to an elevated production of
reactive oxygen species; NDI1 expression can suppress ROS
formation in neuronal cells experiencing rotenone-induced
oxidative stress [37]. These latter results suggest that oxidative
stress associated with neurodegenerative diseases may also be
ameliorated with Ndi1p expression.
In this study, we have further explored the usefulness of Ndi1p
expression in an animal model of complex I deficiency. The
C. elegans strains LB52, LB53 and LB54 contain a point mu-
tation in the nuo-1 gene that alters Ala-352 to Val, reducing
complex I activity to about 30% of wild type [11]. LB52 and
LB53 express the NDI1 gene under the control of the constitutive
let-858 and the nuo-1 promoters, respectively. Ndi1p improves
the overall fitness of these transgenic animals, increasing their
fertility, their respiratory capabilities and their resistance to
oxidative stress. Ndi1p significantly decreased the number of
vacuolar structures that developed in aging animals. Further
investigation will be required to determine whether the lesser
number of vacuoles is a result of decreased necrotic or apoptotic
cell death.
Ndi1p provides an alternative pathway for electrons from
NADH to enter the respiratory chain. We have shown that
Ndi1p expression increases the mitochondrial membrane
potential. This is a highly significant finding because Ndi1p is
not a proton pumping enzyme. The increases in mitochondrial
membrane potential are due to the increased activity of the
respiratory chain and the concomitant proton pumping at
complexes III and IV. The nuo-1 A352V mutation impairs the
oxidation of NADH, the major respiratory substrate. The
development of a method to assess in vivo mitochondrial
membrane potential offers numerous advantages in understand-
ing the complex relationship between genotype and phenotype
in mitochondrial disease. The mitochondrial membrane poten-
tial is directly linked to important cellular processes such ATP
synthesis, ion and metabolite transport and the production of
reactive oxygen species.
The significant improvements in animal fitness we observed
indicate that the NDI1 gene can be expressed and that the Ndi1p
precursor can be targeted to and imported into nematode
mitochondria. Furthermore, Ndi1p can recruit its FAD cofactor
and fold into a functional protein in the inner membrane,
although the efficiency of these processes varied considerably
between independently-derived transgenic lines. These obser-
vations attest to the extensive similarities between mitochondria
1162 A. DeCorby et al. / Biochimica et Biophysica Acta 1767 (2007) 1157–1163of extremely divergent species and confirm the versatility of
Ndi1p.
Ndi1p expression cannot complement a complete loss of
complex I. The nuo-1(ua1) allele is a lethal deletion that results in
larval arrest [38]. We have attempted to directly rescue the nuo-1
(ua1) induced larval arrest by injectingNDI1 under the control of a
variety of promoters into nuo-1(ua1) heterozygotes and isolating
ua1 homozygous progeny. We have never succeeded in isolating
a viable homozygous nuo-1(ua1) animal. Our best attempts have
been with a heat shock-inducible promoter that resulted in the
occasional production of L4 larvae or sterile adults. Why does
Ndi1p expression fail to support viability in animals lacking
complex I? One possible explanation is that we have not achieved
sufficiently high expression levels of functional Ndi1p. We have
noted that expression levels are highly variable between inde-
pendently isolated lines (Fig. 3). A second explanation might be
that Ndi1p is not functionally expressed in one or more tissues
essential for viability in the absence of complex I. We have used
constitutive promoters to drive ubiquitous expression, but we
cannot rule out this possibility. Finally, a third possibility is that
complex I performs one or more additional functions besides its
role in electron transport and NADH oxidation. With 45 subunits
in the human complex I, it seems likely that this may be the case.
Complex I may have a significant role in regulating apoptosis
[39,40] or in redox signaling [41]. One of the complex I accessory
subunits is a homolog of acyl carrier proteins and may have a role
in lipoic acid biosynthesis [42]. Finally, there ismounting evidence
that complex I can be found in respiratory supercomplexes [42,43];
we have shown that complex I deficiency can affect the levels of
complex IV [25]. Ndi1p expression produces significant benefits
in our nematode model of complex I deficiency and may likewise
produce benefits in patients. Our inability to replace complex I
with Ndi1p should stimulate further investigations aimed at better
understanding the structure and function of complex I.
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